BriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
09 September 2024 - 9:50PM
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT)
(“BriaCell” or the “Company”), a clinical-stage biotechnology
company that develops novel immunotherapies to transform cancer
care, announces a poster presentation at the Society for
Immunotherapy of Cancer (SITC) 39th Annual Meeting, held November
6-10, 2024, in Houston, TX.
“We are thrilled to be invited to present our
data at this prestigious conference,” stated Miguel Lopez-Lago,
PhD, BriaCell’s Chief Scientific Officer. “We look forward to
continuing our investigations of novel targeted immunotherapy
candidates in clinical studies with the goal of making a positive
contribution to the lives of breast cancer and prostate cancer
patients.”
The details about the presentation and session
Information are as follows:
Location: Exhibit Halls A
B George R. Brown Convention Center, Houston, TX Date and
Time: Friday, Nov. 8, 2024, 9:00 am -7:00 pm CST
Following the presentation, a copy of the poster
will be posted
on https://briacell.com/scientific-publications/.
About BriaCell Therapeutics
Corp.
BriaCell is a clinical-stage biotechnology
company that develops novel immunotherapies to transform cancer
care. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” “will,” “would,” or the negative of
these words or other similar expressions, although not all
forward-looking statements contain these words. Forward-looking
statements, including those about BriaCell continuing its clinical
study investigations of its novel targeted immunotherapy
candidates, are based on BriaCell’s current expectations and are
subject to inherent uncertainties, risks, and assumptions that are
difficult to predict. Further, certain forward-looking statements,
such as those are based on assumptions as to future events that may
not prove to be accurate. These and other risks and uncertainties
are described more fully under the heading “Risks and
Uncertainties” in the Company’s most recent Management’s Discussion
and Analysis, under the heading “Risk Factors” in the Company’s
most recent Annual Information Form, and under “Risks and
Uncertainties” in the Company’s other filings with the Canadian
securities regulatory authorities and the U.S. Securities and
Exchange Commission, all of which are available under the Company's
profiles on SEDAR+ at www.sedarplus.ca and on
EDGAR at www.sec.gov. Forward-looking statements
contained in this announcement are made as of this date, and
BriaCell Therapeutics Corp. undertakes no duty to update such
information except as required under applicable law.
Neither the Toronto Stock Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Toronto Stock Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Contact Information
Company Contact:William V.
Williams, MDPresident &
CEO1-888-485-6340info@briacell.com
Media Relations:Jules AbrahamCORE
IRjulesa@coreir.com
Investor Relations Contact:CORE
IRinvestors@briacell.com
BriaCell Therapeutics (NASDAQ:BCTXW)
Historical Stock Chart
From Aug 2024 to Sep 2024
BriaCell Therapeutics (NASDAQ:BCTXW)
Historical Stock Chart
From Sep 2023 to Sep 2024